Vol 16, No 2 (2020)
Guidelines / Expert consensus
Published online: 2020-05-15

open access

Page views 1535
Article views/downloads 2247
Get Citation

Connect on Social Media

Connect on Social Media

Systemic treatment of patients with solid tumors during the COVID-19 (SARS-CoV-2) pandemic — comprehensive recommendations of the Polish Society of Clinical Oncology

Piotr J Wysocki1, Łukasz Kwinta1, Paweł Potocki1, Kamil Konopka1, Joanna Streb1, Marek Z Wojtukiewicz2, Barbara Radecka34, Piotr Tomczak5, Michał Jarząb6, Andrzej Kawecki7, Maciej Krzakowski7
Oncol Clin Pract 2020;16(2):41-51.


Not available

Article available in PDF format

View PDF Download PDF file


  1. Anon. WORLDOMETER.INFO. Available at: https://www.worldometers.info/coronavirus/. Accessed April 1, 2020.
  2. Wysocki PJ, Kwinta Ł, Potocki P, et al. Leczenie systemowe pacjentów z rozpoznaniem choroby nowotworowej w kontekście pandemii SARS-CoV-2 — stanowisko Polskiego Towarzystwa Onkologii Klinicznej. Onkol Prakt Klin Edu. 2020; 6.
  3. Guan WJ, Ni ZY, Hu Yu, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 [Epub ahead of print].
  4. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21(3): 335–337.
  5. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020 [Epub ahead of print].
  6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 [Epub ahead of print].
  7. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008; 26(5): 778–785.
  8. van Hagen P, Hulshof MC, van Lanschot JJB, et al. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22): 2074–2084.
  9. Di Lauro L, Vici P, Belli F, et al. Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. Gastric Cancer. 2014; 17(4): 718–724.
  10. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018; 379(25): 2395–2406.
  11. Mirkin KA, Greenleaf EK, Hollenbeak CS, et al. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer. Cancer. 2016; 122(19): 2979–2987.
  12. Ma SJ, Oladeru OT, Miccio JA, et al. Association of timing of adjuvant therapy with survival in patients with resected stage I to II pancreatic cancer. JAMA Netw Open. 2019; 2(8): e199126.
  13. Facciorusso A, Bellanti F, Villani R, et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A meta-analysis of randomized trials. United European Gastroenterol J. 2017; 5(4): 511–518.
  14. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012; 13(6): 579–588.
  15. Hüttner FJ, Probst P, Kalkum E, et al. Addition of platinum derivatives to fluoropyrimidine-based neoadjuvant chemoradiotherapy for stage II/III rectal cancer: systematic review and meta-analysis. J Natl Cancer Inst. 2019; 111(9): 887–902.
  16. Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018; 378(13): 1177–1188.
  17. Boyne DJ, Cuthbert CA, O'Sullivan DE, et al. Association between adjuvant chemotherapy duration and survival among patients with stage II and III colon cancer: a systematic review and meta-analysis. JAMA Netw Open. 2019; 2(5): e194154.
  18. Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005; 352(26): 2696–2704.
  19. Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol. 2009; 27(8): 1177–1183.
  20. Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017; 35(23): 2647–2655.
  21. Watanabe T, Kuranami M, Inoue K, et al. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer. 2017; 123(5): 759–768.
  22. Bradley R, Braybrooke J, et al. Gray R, Bradley R, Braybrooke J, et al. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019.
  23. Slamon D, Eiermann W, Robert N, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273–1283.
  24. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011; 29(25): 3366–3373.
  25. Sparano JA, Zhao F, Martino S, et al. Long-Term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015; 33(21): 2353–2360.
  26. Arriagada R, Bergman B, Dunant A, et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350(4): 351–360.
  27. Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: Results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014.
  28. Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020.
  29. Toyama T, Yamashita H, Hara Y, et al. Biweekly paclitaxel in patients with metastatic breast cancer. Int J Clin Oncol. 2003; 8(6): 357–361.
  30. Camerini A, Banna GL, Cinieri S, et al. Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis. Clin Transl Oncol. 2019; 21(6): 790–795.
  31. De Iuliis F, Salerno G, Taglieri L, et al. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori. 2015; 101(1): 30–35.
  32. Cazzaniga ME, Munzone E, Bocci G, et al. Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. Adv Ther. 2019; 36(2): 381–406.
  33. Baselga J, Kim S, Im S. Pertuzumab plus trastuzumab plus docetaxel for mBC (CLEOPATRA Study Group). N Engl J Med. 2012.
  34. Miles D, Im YH, Fung A, et al. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol. 2017; 28(11): 2761–2767.
  35. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011; 29(3): 264–271.
  36. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for her2-positive advanced breast cancer. N Engl J Med. 2012; 367(19): 1783–1791.
  37. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017; 18(6): 779–791.
  38. Chan JK, Brady MF, Monk BJ, et al. Weekly vs. Every-3-Week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016; 374(8): 738–748.
  39. Cutsem EV, Lang I, Folprecht G, et al. Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. J Clin Oncol. 2010; 28(15_suppl): 3570–3570.
  40. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28(31): 4697–4705.
  41. Pietrantonio F, Caporale M, Berenato R, et al. First-line FOLFOX-4 plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients (pts) with RAS wild-type, metastatic colorectal cancer (mCRC): The VALENTINO study. J Clin Oncol. 2016; 34(15_suppl): TPS3634–TPS3634.
  42. Aparicio T, Ghiringhelli F, Boige V, et al. PRODIGE 9 Investigators. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol. 2018; 36(7): 674–681.
  43. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28): 3499–3506.
  44. Bang YJ, Cutsem EV, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742): 687–697.
  45. Wysocki P. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Targeted Therapies for Renal Cell Carcinoma. 2011: 16–26.
  46. Wysocki PJ. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn. 2009; 9(3): 231–241.
  47. Hudes GR, Carducci MA, Choueiri TK, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22): 2271–2281.
  48. Arabi YM, Mandourah Y, Al-Hameed F, et al. Saudi Critical Care Trial Group. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018; 197(6): 757–767.
  49. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006; 3(9): e343.
  50. Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129(6): 1441–1452.
  51. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004; 31(4): 304–309.
  52. Anon WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection. Date Jan 28, 2020 Date accessed Febr 9, 2020.
  53. Shang L, Zhao J, Hu Yi, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020; 395(10225): 683–684.
  54. Rabenau HF, Cinatl J, Morgenstern B, et al. Stability and inactivation of SARS coronavirus. Med Microbiol Immunol. 2005; 194(1-2): 1–6.
  55. Anon. European Centre for Disease Prevention and Control. Cloth masks and mask sterilisation as options in case of shortage of surgical masks and respirators – 26 March 2020. Stockholm: ECDC; 2020.
  56. Viscusi DJ, Bergman MS, Eimer BC, et al. Evaluation of five decontamination methods for filtering facepiece respirators. Ann Occup Hyg. 2009; 53(8): 815–827.
  57. Lindsley WG, Martin SB, Thewlis RE, et al. Effects of Ultraviolet Germicidal Irradiation (UVGI) on N95 Respirator Filtration Performance and Structural Integrity. J Occup Environ Hyg. 2015; 12(8): 509–517.
  58. Anon. Decontamination and Reuse of Filtering Facepiece Respirators using Contingency and Crisis Capacity Strategies. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/decontamination-reuse-respirators.html. Accessed March 4, 2020.